<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1049">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04365231</url>
  </required_header>
  <id_info>
    <org_study_id>HASCOPT2020</org_study_id>
    <nct_id>NCT04365231</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial</brief_title>
  <acronym>HASCOPT</acronym>
  <official_title>Efficacy Evaluation of Hydroxychloroquine Azithromycin in the Treatment of COVID-19 in Pregnant Women: an Open-label Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital St. Joseph, Marseille, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital St. Joseph, Marseille, France</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Up to date, and since December 31st 2019, 2 520 522 cases of COVID-19 including 176 786&#xD;
      deaths, have been reported worldwide. Global efforts are made to save lives and decrease&#xD;
      morbidity by evaluating therapeutic strategies. Pregnant women with COVID-19 are at high-risk&#xD;
      of severe complications and mortality from COVID-19 infection, due to physiologic and immune&#xD;
      changes occurring during pregnancy. These risks include development of maternal hypoxemic&#xD;
      respiratory failure due to severe pneumonia, hospitalization in intensive care, death; but&#xD;
      also, fetal morbidity-mortality with chronic and/or acute fetal distress, intrauterine growth&#xD;
      retardation, intrauterine death and neonatal morbidity, mainly due to induced preterm birth&#xD;
      and maternal-fetal transmission. Knowledge of these epidemiologic facts on SARS-Cov-2&#xD;
      infection in pregnant women is currently limited to small case-series. No drug has&#xD;
      demonstrated solid evidence in treating SARS-Cov-2 virus. Nevertheless, in vitro studies and&#xD;
      tests in COVID-19 positive patients treated with hydroxychloroquine and azithromycin merit&#xD;
      further evaluation. Pregnant women are systematically excluded from drug trials, and&#xD;
      treatment options for this high-risk population remain untested. The aim of this study is to&#xD;
      screen pregnant women presenting minor symptoms, for COVID-19 and to evaluate efficacy of&#xD;
      hydroxychloroquine-azithromycin treatment in preventing aggravation of symptoms with&#xD;
      development of hypoxemic respiratory failure and complications of pregnancy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no authorization obtained&#xD;
  </why_stopped>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with a negative RT-PCR test result to COVID-19</measure>
    <time_frame>7 days</time_frame>
    <description>Percentage of patients with a negative RT-PCR test result to COVID-19 nasopharyngeal swab at the 7th day of treatment by hydroxychloroquine and azithromycin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal outcomes: Percentage of severe forms of the disease</measure>
    <time_frame>25 weeks</time_frame>
    <description>percentage of severe forms of the disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Newborn outcomes: Rate of newborns hospitalized in intensive care or transferred to resuscitation unit</measure>
    <time_frame>25 weeks</time_frame>
    <description>rate of newborns hospitalized in intensive care or transferred to resuscitation unit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>COVID19</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine and azithromycin treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hydroxychloroquine 10-day course of hydroxychloroquine 200 mg tablet three times a day. To be taken orally.&#xD;
- azithromycin 5-day course of azithromycin 250 mg tablet twice a day on the first day of treatment, then once a day the 4 following days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional management of patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regular management of patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine and azithromycin treatment</intervention_name>
    <description>hydroxychloroquine 10-day course of hydroxychloroquine 200 mg tablet three times a day. To be taken orally.&#xD;
- azithromycin 5-day course of azithromycin 250 mg tablet twice a day on the first day of treatment, then once a day the 4 following days.</description>
    <arm_group_label>Hydroxychloroquine and azithromycin treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>conventional management of patients</intervention_name>
    <description>conventional management of patients</description>
    <arm_group_label>Hydroxychloroquine and azithromycin treatment</arm_group_label>
    <arm_group_label>conventional management of patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  pregnant&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
          -  monofetal pregnancy between 22+0 and 41+0 weeks of gestation&#xD;
&#xD;
          -  presenting a positive COVID-19 RT-PCR test result after nasopharyngeal swab for one or&#xD;
             more minor symptoms: cough, body temperature &gt;37,3 Â°C, shortness of breath, diarrhea,&#xD;
             asthenia, anosmia, taste loss, myalgia&#xD;
&#xD;
          -  presenting no contraindication to hydroxychloroquine and azithromycin&#xD;
&#xD;
          -  informed consent signature&#xD;
&#xD;
          -  affiliated to social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergic to hydroxychloroquine or chloroquine, or azithromycin&#xD;
&#xD;
          -  contraindication to hydroxychloroquine: retinopathy, G6PD deficiency, long QT&#xD;
             syndrome, any other heart rhythm abnormality on pre-recruitment electrocardiogram,&#xD;
             hypokalemia, porphyria, psoriasis.&#xD;
&#xD;
          -  contraindication to azithromycin: long QT syndrome, liver failure, myasthenia&#xD;
&#xD;
          -  receiving simultaneous treatments contraindicated in case of hydroxychloroquine&#xD;
             uptake: Citalopram (Seropram), escitalopram (Seroplex), hydroxyzin (Atarax),&#xD;
             domperidone (Motilium), piperaquine (Eurartesim), disopyramide (Isorythm, Rythmodan),&#xD;
             hydroquinidine chlorydrate (Serecor), amiodarone (Cordarone), dronedaron (Multaq),&#xD;
             tricyclic antidepressant, anti-infectious drugs (macrolids, fluoroquinolones,&#xD;
             trimethoprime-sulfamethoxazole (Bactrim).&#xD;
&#xD;
          -  receiving simultaneous treatments contraindicated in case of azithromycin uptake:&#xD;
             Cisapride, Colchicine, Dihydroergotamine, bromocriptine, cabergoline, lisurid,&#xD;
             pergolide, atorvastatin, ciclosporin, digoxin, simvastatin, anti-vitamine K,&#xD;
             macrolids, ketolide&#xD;
&#xD;
          -  hypoxemic respiratory failure due to severe pneumonia (needing supplemental oxygen)&#xD;
&#xD;
          -  maternal disorders: Type I or II diabetes, congenital cardiopathy, liver or kidney&#xD;
             disease, liver failure, renal failure&#xD;
&#xD;
          -  obstetrical disorders: insulin-dependent gestational diabetes, preterm delivery&#xD;
             threat, preterm rupture of membranes, bleeding, pre-eclampsia, gestational&#xD;
             hypertension, gestational cholestasis&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-Cov-2 virus</keyword>
  <keyword>coronavirus disease</keyword>
  <keyword>COVID-19</keyword>
  <keyword>epidemic</keyword>
  <keyword>pregnancy</keyword>
  <keyword>RT-PCR</keyword>
  <keyword>hydroxychloroquine</keyword>
  <keyword>azithromycin</keyword>
  <keyword>respiratory distress</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

